Lothar Kunze

- Leitung Geschäftsbereich Onkologie in Australien & New Zealand - Umsatz- und Gewinnverantwortung: über 100 Mio US$ - Anzahl Mitarbeiter: ca. 80 (Vertrieb, Marketing & Medizin) - Markteinführung von Präparaten im Bereich Immunonkologie (Lungenkrebs), sowie zielgerichteter Krebstherapie in verschiedenen soliden Tumoren und Hämatologie

- Auf- und Ausbau der Onkologieorganisation (Marketing & Vertrieb) in der Emerging Markets Region (Asien, Latein Amerika, Russland, Naher- und Mittler Osten, Australien) - Strategische Planung und taktische Umsetzung - Mitglied des globalen Onkologie Leitungsteams - Business Development und management von Lizenzpartnern

• Led team of Commercial Directors across Europe, Emerging Markets & Asia • Developed capabilities focusing on launch & execution excellence, pricing & market access and sales force excellence • Steering Committee & Alliance Management • Provided strategic input/direction/decision as member of Global Oncology Leadership Team • GSK/Novartis Integration Team: Transitioned GSK’s Oncology business and people to Novartis after completion of GSK Oncology acquisition by Novartis in Mar 2015

• Shaped & implemented global Oncology strategy across Asia (focus on launch & sales excellence, market access) • Led commercial alliance management team (Amgen collaboration) • Launched: Votrient (renal cell cancer), Revolade (ITP), Tafinlar/Mekinist (melanoma), Arzerra (CLL), XGEVA (bone metastases) & Vectibix (CRC)

• Implemented global Oncology strategy across Asia (focus on launch & execution excellence, market access) • Developed commercial strategy as member of Global Oncology Commercial Board representing Asia • Led commercial alliance management team (Amgen collaboration) • Reported to Head, Emerging Markets, Global Oncology

• Developed and implemented commercial strategy for Oncology portfolio across Asia-Pacific & Australasia • Created and managed (incl. direct-line headcount & full P&L accountability of) sub-region “South-East Asia Oncology Business Unit” (5 direct reports, team of 45 reports) within the broader Asia Pacific region • Led commercial alliance management partnership with Amgen • Reported to Regional VP Commercial Operations, Asia-Pacific

• Full P&L, balance sheet and people accountability • 11 direct reports and 220 team members across 11 Asia-Pacific markets • Launched Erbitux (colorectal and H&N cancer) across Asia-Pacific incl. China • Reported to MerckSerono board, EVP Oncology

• Ensured launch of Erbitux via mainly 3rd-party partnerships across the Middle-East/Africa region • Managed P&L and teams across the Intercontinental region (mainly MEA and Russia/CIS), incl. business plan review process • Reported to MerckSerono board, EVP Oncology

• Developed global brand/launch strategy for Erbitux (colorectal and head-and-neck cancer) for Merck in-licensed territory (ex-US) • Developed and implemented full range of global launch initiatives, incl. global external expert management, agency management, • Co-developed publications/literature database in partnership with Medical Affairs • Developed and coordinated global brand plan review process • Reported to Global Head, Strategic Marketing

Naturwissenschaftlicher-medizinischer Teil: Allgemeine Grundlagen Chemie, Physik, Biologie. Anatomie und Physiologie, Pathologie. Pharmazie, spezielle Pharmakologie, Biochemie. Rechtskunde

Industriebetriebslehre, Rechnungswesen, Organisation, Automatisierte Datenverarbeitung, Wirtschafts- und Sozialkunde

Business Studies

Mathematik, Wirtschaftslehre (Business Studies), Erdkunde, Deutsch